Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 06, 2022 07:00 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

STAMFORD, Conn., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
August 24, 2022 07:00 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics to Host Virtual Notalgia Paresthetica Event on September 20, 2022

STAMFORD, Conn., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
August 22, 2022 07:00 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics Announces KOMFORT Data Accepted for Late-Breaking Presentation at the 31st EADV Congress

STAMFORD, Conn., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
August 19, 2022 01:00 ET | Source: Cara Therapeutics, Inc.

Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022

Kapruvia® (difelikefalin) is the first and only therapy approved through consortium filing for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients Therapy...
August 08, 2022 16:01 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics Reports Second Quarter 2022 Financial Results

– Net revenue was $23M for 2Q 2022 comprised of profit-sharing revenue of $8M from KORSUVA™ (difelikefalin) injection and a $15M milestone payment from the European Commission approval of Kapruvia®...
August 03, 2022 07:00 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference

STAMFORD, Conn., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
August 01, 2022 16:01 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics to Announce Second Quarter 2022 Financial Results on August 8, 2022

STAMFORD, Conn., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
June 30, 2022 07:00 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica

– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) – – Onset of action seen at Week 1 and sustained through Week 8 – – Statistical...
May 17, 2022 07:00 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics to Present at Upcoming Investor Conferences

STAMFORD, Conn., May 17, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
May 09, 2022 16:01 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics Reports First Quarter 2022 Financial Results

KORSUVA™ (difelikefalin) injection U.S. commercial launch began in April 2022 and is tracking to expectation Kapruvia® (difelikefalin) approved by European Commission for the treatment of...